

Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor

INDICATIONS FOR USE:

| INDICATION | ICD10 | Regimen Code | Reimbursement Status |
|--|-------|--------------|----------------------|
| Myeloablative conditioning for mismatched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders | C92 | 00663a | Hospital |

TREATMENT:

Conditioning chemotherapy is administered over **10 days**. Stem cells are infused on **day 0**.

Facilities to treat anaphylaxis **MUST** be present when conditioning therapy and stem cells are administered.

| Day (time) | Drug | Dose | Route | Diluent & Rate |
|--|---------------------------|---------------------|-------------|---|
| -10,-9,-8,-7 (16.30)* | Busulfan ^a | 0.8mg/kg | IV infusion | (See note ^b) ml sodium chloride 0.9% over 2 hours |
| -10,-9,-8,-7 (22.30)* | Busulfan ^a | 0.8mg/kg | IV infusion | (See note ^b) ml sodium chloride 0.9% over 2 hours |
| -9,-8,-7,-6 (04.00)* | Busulfan ^a | 0.8mg/kg | IV infusion | (See note ^b) ml sodium chloride 0.9% over 2 hours |
| -9,-8,-7,-6 (10.30)* | Busulfan ^a | 0.8mg/kg | IV infusion | (See note ^b) ml sodium chloride 0.9% over 2 hours |
| NB: IV busulfan expires after 15 hours, infusion must begin at time specified | | | | |
| -5,-4 (09.30)* | Mesna | 24mg/kg | IV push | Give as an IV push via side-arm of a fast-flowing sodium chloride 0.9% infusion |
| -5,-4 (10:00)* | Cyclophosphamide | 60 mg/kg | IV infusion | 1000mls of sodium chloride 0.9% over 3 hours |
| -5, -4 (13.00)* | Mesna | 24mg/kg | IV push | Give as an IV push via side-arm of a fast-flowing sodium chloride 0.9% infusion |
| -5, -4 (16.00)* | Mesna | 24mg/kg | IV push | Give as an IV push via side-arm of a fast-flowing sodium chloride 0.9% infusion |
| -5, -4 (19.00)* | Mesna | 24mg/kg | IV push | Give as an IV push via side-arm of a fast-flowing sodium chloride 0.9% infusion |
| -5, -4 (22.00)* | Mesna | 24mg/kg | IV push | Give as an IV push via side-arm of a fast-flowing sodium chloride 0.9% infusion |
| -4,-3 (02:00)* | Mesna | 24mg/kg | IV push | Give as an IV push via side-arm of a fast-flowing sodium chloride 0.9% infusion |
| -4, -3 (6.00)* | Mesna | 24mg/kg | IV push | Give as an IV push via side-arm of a fast-flowing sodium chloride 0.9% infusion |
| -3 (10:00)* | Mesna | 24mg/kg | IV push | Give as an IV push via side-arm of a fast-flowing sodium chloride 0.9% infusion |
| -3 | ATG Grafalon® | 20mg/kg | IV infusion | (See note ^c) ml sodium chloride 0.9% over 12 hours ^d |
| -2, -1 | ATG Grafalon® | 20mg/kg | IV infusion | (See note ^c) ml sodium chloride 0.9% over 10 hours ^d |
| 0 | Stem cell infusion | | | |
| +1 (At least 24 hours post completion of stem cell infusion) | Methotrexate ^e | 15mg/m ² | IV infusion | 50mls of sodium chloride 0.9% over 10 minutes |
| +3, +6, +11 | Methotrexate | 10mg/m ² | IV infusion | 50mls of sodium chloride 0.9% over 10 minutes |
| Dose rounding: Busulfan to the nearest 1.2mg if <60mg, to nearest 6mg if >60mg. Oral busulfan available as 2mg and 25mg tablets. | | | | |

| | | |
|--|--|-------------------|
| 1NCCP Regimen: Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor | Published:06/08/2021 Review:01/04/2025 | Version number:1a |
| Tumour Group: Transplant NCCP Regimen Code: 00663 | IHS Contributor: SJH Stem Cell Transplant Group | Page 1 of 9 |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |

| |
|---|
| <p>Mesna to the nearest 100mg, Cyclophosphamide to the nearest 20mg, ATG Grafalon® to the nearest 20mg Methotrexate to the nearest 2.5mg</p> |
| <p>^aIf a problem with an infusion bag (i.e. leaking bag, short expiry) is discovered outside of 8.30am-5pm, an oral dose of busulfan 1mg/kg equivalent to the intravenous dose will be available from the MDA press on Denis Burkitt Ward. This can only be used after discussion with a haematology consultant and must be prescribed by haematology registrar or consultant on a chemotherapy prescription.</p> |
| <p>^bCalculation of busulfan infusion solution: [(busulfan dose (mg) divided by 6) x 10] [to the nearest 10ml] NaCl 0.9% - concentration to be as close to 0.5mg/ml as possible</p> |
| <p>^cEach ml of ATG Grafalon® should be diluted with 6ml sodium chloride 0.9% in accordance with SPC. Pharmacy to complete volume</p> |
| <p>^d Patient monitoring is required during the ATG Grafalon® infusion: BP, pulse, respiration and temperature at 15, 30 and then 60 minute intervals for the duration of the infusion. If a reaction occurs, the infusion should be slowed. Chills and fever generally respond to antihistamines, antipyretics or corticosteroids. If the patient becomes hypotensive or experiences chest or back pain, indicating anaphylaxis, the infusion should be stopped and the medical team contacted immediately. Platelets should be >50x10⁹/L pre day 1 ATG Grafalon® treatment. If the patient has no reaction to ATG Grafalon®, platelets can be maintained at >30x10⁹/L for the remaining days of ATG Grafalon® administration. Platelets should be maintained at >50x10⁹/L in the setting of clinically symptomatic bleeding</p> |
| <p>^eDay +1 methotrexate should be administered at least 24 hours after the stem cells have infused. In the event where this timing results in methotrexate being infused during the night, it is reasonable to reschedule the administration time of the day +3 methotrexate to the next morning, to avoid administration during the night. The amended administration timing can then be maintained for subsequent methotrexate doses.</p> |
| <p>[*]denotes recommended administration time</p> |

ELIGIBILITY:

- Indications as above
- Medical assessment as per SJH BMT assessment form

EXCLUSIONS:

- Hypersensitivity to busulfan, cyclophosphamide, mesna, methotrexate, ATG Grafalon® or any of the excipients.
- Pregnancy and lactation

PRESCRIPTIVE AUTHORITY:

- The treatment plan must be initiated by a Haematology Consultant working in the area of stem cell transplantation in a unit suitable for carrying out this treatment

TESTS:

- Baseline and regular tests in accordance with SJH Haematopoietic Stem Cell Transplant work-up protocols

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant

| | | |
|---|--|--------------------------|
| <p>1NCCP Regimen: Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor</p> | <p>Published:06/08/2021 Review:01/04/2025</p> | <p>Version number:1a</p> |
| <p>Tumour Group: Transplant NCCP Regimen Code: 00663</p> | <p>IHS Contributor: SJH Stem Cell Transplant Group</p> | <p>Page 2 of 9</p> |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer <i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Haematology Consultant.
- **Chemotherapy dosing in obese adult patients:** For patients with a BMI > 30kg/m² please refer to 'Chemotherapy Dosing in Obese Adult Stem Cell Transplant Recipients – Guidelines' for guidance on individual drug dosing as per SJH policy available on the SJH intranet.
- **Renal and Hepatic Impairment:**
 - Dose modifications are generally not undertaken in conditioning regimens.
 - Discuss with the consultant if the creatinine clearance is < 50 ml/min or if abnormal hepatic function.
 - Consult the following resources to inform any renal or hepatic dose modification discussions:
 - Summary of product characteristics (SPC) available at <http://www.hpra.ie>
 - Krens et al Lancet Oncol 2019;20(4) e200-e207 "Dose Recommendations for anticancer drugs in patients with renal or hepatic impairment" available at <https://pubmed.ncbi.nlm.nih.gov/30942181/>
 - UCHL renal impairment guidelines and hepatic impairment guidelines available on SJH intranet.

SUPPORTIVE CARE:

Antiemetics

Table 1: Recommended SJH Regimen Specific Antiemetics

| Prevention of acute emesis | | | Prevention of delayed emesis | Comments |
|----------------------------|---------------|-----------|---|---|
| Drug | Dose | Admin day | No additional dexamethasone is required due to steroid cover with ATG Grafalon® | Exclude aprepitant due to cyclophosphamide/aprepitant interaction |
| Ondansetron | 8mg PO/IV TDS | -10 to -4 | | |
| Dexamethasone | 12mg PO | -5, -4 | | |

Cyclophosphamide hydration and diuresis:

- Pre stem cell infusion: Start pre-hydration at 6.00 am on Day -5
 - Recommended hydration regimen is sodium chloride 0.9% 2-3L/m² over 24 hours
- Continue hydration for at least 24 hours after completion of cyclophosphamide
- Diuretics may be indicated for positive fluid balance, weight gain or declining urine production (<100ml/m²/hr)
 - Furosemide 20-40mg IV PRN should be prescribed

Busulfan conditioning seizure prophylaxis:

- Phenytoin 600mg STAT orally at midnight the night before busulfan treatment, then 300mg once daily PO on day -10 to day -6

| | | |
|--|--|-------------------|
| 1NCCP Regimen: Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor | Published:06/08/2021 Review:01/04/2025 | Version number:1a |
| Tumour Group: Transplant NCCP Regimen Code: 00663 | IHS Contributor: SJH Stem Cell Transplant Group | Page 3 of 9 |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |

ATG Grafalon® supportive medications:

- Methylprednisolone 2mg/kg once daily IV 90mins before commencing ATG on Day -3 to Day -1
- Chlorphenamine 10mg IV 30mins before commencing ATG on Day -3 to Day -1
- Prednisolone 1mg/kg once daily PO (or an equivalent IV alternative starting on Day 0 and continuing for 5 days)
- Taper to zero over next 5 days to prevent serum sickness

OTHER SUPPORTIVE CARE:

Table 2: Recommended SJH regimen specific supportive care

| | |
|---|---|
| <p>GvHD prophylaxis: Refer to signed off BMT assessment form for confirmed choice and target level of immunosuppression</p> | <p>Tacrolimus</p> <ul style="list-style-type: none"> • 0.03mg/kg once daily IV over 22 hours, starting from day -1 • The equivalent oral dose is: (Total IV dose) twice daily PO • Target levels: 5-10 nanogram/ml |
| <p>GvHD and VOD prophylaxis</p> | <ul style="list-style-type: none"> • Ursodeoxycholic acid 250mg TDS PO • Continue until day +90 |
| <p>HSV prophylaxis</p> | <p>All patients should receive the following until CD4 count >200/microlitre:</p> <ul style="list-style-type: none"> • Valaciclovir 500mg once daily PO Or • Aciclovir 250mg TDS IV (if oral route not available or ANC < 0.5x10⁹/L) <p>Patients with an active herpes infection should receive the following:</p> <ul style="list-style-type: none"> • Valaciclovir 1g TDS PO Or • Aciclovir 10mg/kg TDS IV (if oral route not available) |
| <p>CMV prophylaxis Prescribe for all CMV seropositive recipients</p> | <p>Patients receiving CMV prophylaxis with letermovir also require HSV prophylaxis above</p> <ul style="list-style-type: none"> • Letermovir 480mg once daily PO/IV, as appropriate, starting Day +1 if patient is receiving tacrolimus immunosuppression • Letermovir via the oral route is first line. • Letermovir IV at the same oral dose should be prescribed only where the patient cannot tolerate oral or where there are concerns around absorption • CMV prophylaxis is usually continued until day +100 <p>Patients should bring their oral letermovir supply with them on admission. High tech prescription will have been provided to patient at their counselling appointment pre-admission. Liaise with transplant pharmacist if any supply issues arise.</p> <p>When ANC > 1.0 x 10⁹/L, pre-emptive monitoring (9mls in EDTA [purple tube] (Tuesday and Fridays) should be carried out for CMV reactivation/infection in <u>all</u> patients.</p> |

| | | |
|---|--|--------------------------|
| <p>1NCCP Regimen: Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor</p> | <p>Published:06/08/2021 Review:01/04/2025</p> | <p>Version number:1a</p> |
| <p>Tumour Group: Transplant NCCP Regimen Code: 00663</p> | <p>IHS Contributor: SJH Stem Cell Transplant Group</p> | <p>Page 4 of 9</p> |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer <i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |

| | |
|---|---|
| <p>Antifungal prophylaxis Refer to signed off BMT assessment form for confirmed choice of antifungal prophylaxis</p> | <p>When ANC < 0.5 x 10⁹/L or if patient on high dose steroids</p> <ul style="list-style-type: none"> • Liposomal amphotericin® 1mg/kg once daily IV Mon/Wed/Fri Or • Caspofungin 70mg/kg once daily IV Mon/Wed/Fri <p>If at higher risk due to prior possible/probable fungal infection:</p> <ul style="list-style-type: none"> • Liposomal amphotericin® 1mg/kg once daily IV Or • Caspofungin 70mg once daily IV if >80kg Or • Caspofungin 70mg once daily IV on day 1 of treatment and 50mg once daily IV thereafter if <80kg |
| <p>PJP prophylaxis</p> | <p><u>First line therapy</u></p> <ul style="list-style-type: none"> • Co-trimoxazole 960mg BD Mon/Wed/Fri PO • Commence only on engraftment when ANC > 1.0x10⁹/L if appropriate <p><u>Second line therapy (if allergic to co-trimoxazole or contraindicated):</u> <i>PJP Prophylaxis and T. gondii IgG NEGATIVE</i></p> <ul style="list-style-type: none"> • Pentamidine 300mg nebule and salbutamol 2.5mg nebule pre-pentamidine, every 4 weeks Plus • Phenoxymethylpenicillin 333mg BD daily PO <p>Continue the phenoxymethylpenicillin until patients have been revaccinated and have adequate pneumococcal/haemophilus titres</p> <p><i>PJP prophylaxis and T.gondii IgG POSITIVE</i></p> <ul style="list-style-type: none"> • Atovaquone 750mg BD PO plus • Pyrimethamine 25mg once daily PO plus • Folinic acid 15mg once daily PO plus • Phenoxymethylpenicillin 333mg BD daily PO <p>Continue the phenoxymethylpenicillin until patients have been revaccinated and have adequate pneumococcal/haemophilus titres</p> <p>Please note: If a patient is to be discharged on atovaquone, pyrimethamine or folinic acid, please contact pharmacy in advance to arrange supply and funding through a community drugs scheme</p> |

| | | |
|---|--|--------------------------|
| <p>1NCCP Regimen: Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor</p> | <p>Published:06/08/2021 Review:01/04/2025</p> | <p>Version number:1a</p> |
| <p>Tumour Group: Transplant NCCP Regimen Code: 00663</p> | <p>IHS Contributor: SJH Stem Cell Transplant Group</p> | <p>Page 5 of 9</p> |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer <i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |

| | |
|--|--|
| Mouthcare: | <p>Mucositis WHO grade < 2:</p> <ul style="list-style-type: none"> Sodium chloride 0.9% 10ml QDS mouthwash Nystatin 1ml QDS PO (use 15 minutes after sodium chloride 0.9% mouthwash) <p>Mucositis WHO grade ≥2:</p> <ul style="list-style-type: none"> Chlorhexidine digluconate 0.12% (Kin® mouthwash) 10ml QDS mouthwash Nystatin 1ml QDS PO (use 15 minutes after Kin® mouthwash) |
| Gastroprotection: | <ul style="list-style-type: none"> Lansoprazole 30mg /omeprazole 40mg once daily PO Or Esomeprazole 40mg once daily IV (if oral route not available) |
| Folate supplementation: | <p>Methotrexate is included as GvHD prophylaxis. Folinic acid should not be administered on the same days as methotrexate</p> <p>The first dose of folinic acid must be administered at a minimum of 24 hours post completion of methotrexate. Prescribe as outlined below:</p> <ul style="list-style-type: none"> Folinic acid 15mg once daily IV on days +2,+4,+5,+7,+8,+9,+10 and +12 onwards Switch to folic acid 5mg once daily PO when oral route is available |
| Vitamin K supplementation | <p>Beginning on day + 2 post stem cell transplant</p> <ul style="list-style-type: none"> Vitamin K (phytomenadione) 10mg once weekly IV |
| Prevention of vaginal bleeding; | <p>If required for menstruating female patients until platelets > 50 x10⁹/L</p> <ul style="list-style-type: none"> Norethisterone 5mg TDS PO if >55Kg Norethisterone 5mg BD PO if <55kg |
| Tumour Lysis syndrome | <p>Consider allopurinol in active disease pre transplant</p> <ul style="list-style-type: none"> Allopurinol 300mg once daily PO for 5-7 days and review |
| Hepatitis B prophylaxis/treatment | <p>A virology screen is completed as part of transplant workup. Hepatitis B prophylaxis or treatment may be initiated in consultation with a Virology Consultant or Hepatology Consultant if required.</p> <p>Options may include:</p> <ul style="list-style-type: none"> Lamivudine 100mg once daily PO Or Entecavir 500mcg once daily PO |
| Prevention of constipation | <p>Consider laxatives if appropriate e.g.</p> <ul style="list-style-type: none"> Senna two tablets (15mg) nocte PO while on ondansetron. |

| | | |
|--|--|-------------------|
| 1NCCP Regimen: Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor | Published:06/08/2021 Review:01/04/2025 | Version number:1a |
| Tumour Group: Transplant NCCP Regimen Code: 00663 | IHS Contributor: SJH Stem Cell Transplant Group | Page 6 of 9 |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |

| | |
|--|--|
| Antibiotic standing order | <p>Antibiotic standing order should be prescribed for neutropenic sepsis/neutropenic fever based on previous microbiology and renal function</p> <ul style="list-style-type: none"> • Piptazobactam 4.5g QDS IV Plus • Amikacin* 15mg/kg once daily IV <p>*Ciprofloxacin 400mg BD IV may be considered instead of amikacin in cases of renal impairment</p> <p>Refer to local Antimicrobial Guidelines in the Prescriber’s Capsule for antibiotic choice where a patient is allergic to any of the above</p> |
| Magnesium and Potassium Standing order: | Magnesium and potassium standing orders should be prescribed for all transplant patients in accordance with stem cell unit practice as indicated on EPMAR. |
| VTE prophylaxis | Consider VTE prophylaxis in accordance with local SJH policy |
| Bone Health | <p>Consider calcium and vitamin D supplementation prior to discharge for patients who are on high dose steroids. Other medications for maintenance of bone health may need to be considered as appropriate.</p> <ul style="list-style-type: none"> • Calcium carbonate and colecalciferol (Caltrate® 600mg/400unit) One tablet BD |

Hepatic veno occlusive disease (VOD):

- Defibrotide may be prescribed for the treatment of hepatic veno-occlusive disease (VOD) in consultation with the haematology consultant
- Dosing of intravenous Defibrotide :
 - The recommended dose is 6.25mg/kg IV every 6 hours (25mg/kg/day)
 - Calculate the total daily dose. Divide by 200 to calculate the total number of vials needed and split the dose such that the minimum amount of wastage can be achieved.
 - Defibrotide should be administered for a minimum of 21 days and continued until the signs and symptoms of VOD resolve.
 - IV infusion is given over 2 hours (maximum concentration 400mg/100ml NaCl 0.9%)

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS:

- Please refer to the relevant Summary of Product Characteristics and SJH Stem Cell Transplant Programme PPGs for full details.

DRUG INTERACTIONS:

- The relevant Summary of Product Characteristics and current drug interaction databases should be consulted.

| | | |
|--|--|-------------------|
| 1NCCP Regimen: Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor | Published:06/08/2021 Review:01/04/2025 | Version number:1a |
| Tumour Group: Transplant NCCP Regimen Code: 00663 | IHS Contributor: SJH Stem Cell Transplant Group | Page 7 of 9 |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |

REFERENCES:

1. Bone Marrow Transplantation for Leukemia Following a New Busulphan and Cyclophosphamide Regimen; Blood 1987; 70(5): 1382-1388
2. Randomised trial of myeloablative conditioning regimens: busulphan plus cyclophosphamide versus busulphan plus fludarabine; Journal of Clinical Oncology 2012; 31: 701-709
3. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biology of Blood and Marrow Transplantation 2002 ;8(3):145-54
4. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomised studies; The American Society of Haematology 2001: 98(13):3569-73.
5. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: Long term follow-up of a randomised study. Biology of Blood and Marrow Transplantation 2014; 20(1):135-138. Available at <https://pubmed.ncbi.nlm.nih.gov/24141008/>
6. Venous-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management. Bone Marrow Transplantation 2017 Apr;52(4):588-591. Available at <https://pubmed.ncbi.nlm.nih.gov/27892944/>
7. Krens S D, Lassche, Jansman G F G A, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Onco/2019; 20:e201-08. [https://doi.org/10.1016/S1470-2045\(19\)30145-7](https://doi.org/10.1016/S1470-2045(19)30145-7)
8. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network.
9. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009; North London Cancer Network.
10. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V3 2021. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
11. Busilvex[®] Summary of Product Characteristics Accessed November 2020. Available at: https://www.ema.europa.eu/en/documents/product-information/busilvex-epar-product-information_en.pdf
12. Cyclophosphamide Summary of Product Characteristics Accessed November 2020. Available at https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2299-027-002_21122018112109.pdf
13. Methotrexate 1g/10ml Summary of Product Characteristics. Accessed November 2020. Available at https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA0822-206-006_19052021104201.pdf

| | | |
|--|--|-------------------|
| 1NCCP Regimen: Busulfan/Cyclophosphamide/ATG Grafalon [®] – MAC – Mismatched Unrelated Donor | Published:06/08/2021 Review:01/04/2025 | Version number:1a |
| Tumour Group: Transplant NCCP Regimen Code: 00663 | IHS Contributor: SJH Stem Cell Transplant Group | Page 8 of 9 |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |

| Version | Date | Amendment | Approved By |
|---------|------------|---|--------------------------------|
| 1 | 06/08/2021 | | SJH Stem Cell Transplant Group |
| 1a | 09/07/2024 | Extension of review date as agreed with clinical reviewer | NCCP |

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

| | | |
|--|--|-------------------|
| 1NCCP Regimen: Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor | Published:06/08/2021 Review:01/04/2025 | Version number:1a |
| Tumour Group: Transplant NCCP Regimen Code: 00663 | IHS Contributor: SJH Stem Cell Transplant Group | Page 9 of 9 |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |